Innovative Health Solution’s IB-Stim Receives FDA’s Clearance for the Treatment of Functional Abdominal Pain in Irritable Bowel Syndrome

Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019


  • The FDA clearance is based on clinical study results assessing IB-Stim vs PBO in patients with functional abdominal pain associated with Irritable Bowel Syndrome (IBS) aged 11-18 yrs.
  • The study results demonstrated 81% improvement in symptoms with no SAEs & minimal side effects. Additionally, it shows that 70% patients failed to improve with an average of four medications trialed, prior to IBM-Stim treatment
  •  The IB-Stim is a non-surgical device, works by sending electrical impulses into cranial nerve bundle in ear and targets brain areas associated with pain and aids in functional abdominal pain in IBS

Click here to read full press release/ article | Ref: IHS | Image: eMPR